Business Wire

Lilac and Traxys Announce Binding 10-Year Offtake Agreement for Great Salt Lake Lithium Production

12.1.2026 13:00:00 CET | Business Wire | Press Release

Share

Lilac Solutions, a leading provider of direct lithium extraction technology, and Traxys North America, a leading global physical trader and merchant in metals and natural resources, today announced a binding 10-year offtake agreement for lithium carbonate produced at Lilac's Great Salt Lake facility in Utah. The agreement represents a major milestone in advancing the project toward construction and establishes a clear commercial pathway for one of the nearest-term domestic lithium projects in the United States.

Under the terms of the definitive agreement, Traxys will purchase 50,000 tonnes of lithium carbonate over a 10-year period, representing 100% of the planned Phase 1 production capacity. The agreement is take-or-pay, with agreed pricing mechanisms linked to market indices.

The Great Salt Lake Phase 1 facility is designed to produce 5,000 tonnes per annum of battery-grade lithium carbonate, which would nearly double current U.S. lithium carbonate production. The project leverages Lilac's proven Gen 5 ion exchange technology, which achieved 87% lithium recovery on the lake's ultra-low-grade brine (69 mg/L lithium) during successful pilot plant operations completed in 2025.

"Traxys, one of the world's leading lithium traders, has been an excellent partner as we've developed this project, and formalizing this long-term offtake agreement is a key step toward achieving final investment decision," said Raef Sully, chief executive officer of Lilac Solutions. "With FEL-3 engineering complete and regulatory approvals progressing, securing offtake for 100% of planned output moves us closer to construction of a significant new source of domestic lithium."

“Traxys is pleased to enter this 10-year offtake agreement with Lilac to advance our shared vision for a robust U.S. lithium supply chain,” said Martim Facada, managing director lithium trading at Traxys. “Lilac’s unique technology and deep sector experience combined with Traxys’ global market reach, expertise in natural resources and supply chain financing will contribute greatly to bring Lilac's lithium carbonate to market to supply the lithium-ion battery industry.”

The Great Salt Lake project represents one of the most significant near-term opportunities to expand domestic lithium supply. Phase 1 would nearly double current U.S. production, with a future Phase 2 expansion bringing total capacity to 20,000 tpa LCE— close to four times current domestic output.

The facility will use ion exchange media manufactured at Lilac’s Fernley, Nevada facility and will generate local tax revenues and royalties to support lake preservation and create jobs in Utah. Lilac’s non-consumptive process returns lithium-depleted brine to the lake and does not lower lake water levels.

Lilac has completed FEL-3 engineering for the facility and is working with state regulators to finalize permits required for construction and operations.

About Lilac

Lilac delivers modern direct lithium extraction technology that unlocks brine resources to scale supply for global electrification. Lilac's ion exchange technology enables high lithium recovery with minimal water use and no evaporation ponds, providing a sustainable alternative to conventional extraction methods. Lilac's technology has been proven through multiple pilot and demonstration plants globally and is now advancing to commercial scale. Lilac is headquartered in Oakland, California, with manufacturing in Fernley, Nevada. Learn more at lilacsolutions.com.

About Traxys

Traxys is a physical commodity trader and merchant in the metals and natural resources sectors. Its logistics, marketing, distribution, supply chain management, and trading activities are conducted by over 450 employees in over 20 offices worldwide, and its annual turnover is in excess of USD 10 billion. Traxys is engaged in sourcing, trading, marketing, and distributing non-ferrous metals, ferro-alloys, minerals, industrial raw materials, and energy.

The Group serves a broad base of industrial customers and offers a full range of commercial and financial services. Traxys is committed to the highest internationally recognized principles for responsible business conduct, and to ensuring that its operations are equitable, sustainable, and transparent.

Traxys premises its practices on environmental, social, and governance (ESG) standards that enable Traxys to set a leading example for the responsible sourcing and trading of metals and minerals.

To learn more about Traxys, go to: www.traxys.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260112372352/en/

Contacts

Lilac Media Contact:
Elizabeth Pond | VP of Communications & Brand, Lilac
press@lilacsolutions.com

Traxys Media Contact:
FGS Global
traxys-global@fgsglobal.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye